Avalyn Pharma Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Avalyn Pharma Inc. (AVLN) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$28.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-12
- Avalyn Pharma Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$28.93M.
- Avalyn Pharma Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$26.87M.
- Avalyn Pharma Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$20.19M.
- Avalyn Pharma Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$17.50M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month |
|---|---|---|
| 2026-06-30 | -$28.93M 10-Q · filed 2026-08-12 | -$55.80M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$26.87M 10-Q · filed 2026-06-03 | |
| 2025-06-30 | -$20.19M 10-Q · filed 2026-08-12 | -$37.69M 10-Q · filed 2026-08-12 |
| 2025-03-31 | -$17.50M 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |